[go: up one dir, main page]

AU1219400A - Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease - Google Patents

Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease

Info

Publication number
AU1219400A
AU1219400A AU12194/00A AU1219400A AU1219400A AU 1219400 A AU1219400 A AU 1219400A AU 12194/00 A AU12194/00 A AU 12194/00A AU 1219400 A AU1219400 A AU 1219400A AU 1219400 A AU1219400 A AU 1219400A
Authority
AU
Australia
Prior art keywords
methods
proliferative disease
screening
risk
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU12194/00A
Inventor
Andrea Amalfitano
Rose-Mary N. Boustany
Wei-Xing Guo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU1219400A publication Critical patent/AU1219400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G01N33/5758
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU12194/00A 1998-10-22 1999-10-21 Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease Abandoned AU1219400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10526298P 1998-10-22 1998-10-22
US60105262 1998-10-22
PCT/US1999/024695 WO2000023624A1 (en) 1998-10-22 1999-10-21 Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease

Publications (1)

Publication Number Publication Date
AU1219400A true AU1219400A (en) 2000-05-08

Family

ID=22304865

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12194/00A Abandoned AU1219400A (en) 1998-10-22 1999-10-21 Methods of screening for risk of proliferative disease and methods for the treatment of proliferative disease

Country Status (2)

Country Link
AU (1) AU1219400A (en)
WO (1) WO2000023624A1 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE911115A1 (en) * 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US5998582A (en) * 1991-05-16 1999-12-07 Cold Spring Harbor Laboratory D-type cyclins and uses related thereto
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
DE69434470T2 (en) * 1993-02-09 2006-06-22 The Johns Hopkins University School Of Medicine NUCLEUS MATRIX PROTEINS
US5789184A (en) * 1993-03-31 1998-08-04 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
US5549974A (en) * 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5886186A (en) * 1995-10-25 1999-03-23 Versicor, Inc. Synthesis of substituted N-heteroaromatic compounds and methods of use thereof

Also Published As

Publication number Publication date
WO2000023624A9 (en) 2000-09-21
WO2000023624A1 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU2212299A (en) Compositions and methods for the treatment of tumor
AU6528800A (en) Methods and apparatuses for radiation treatment
AU7264298A (en) Apparatus and method for the reduction of snoring
AU2092697A (en) Combinations for treatment of proliferative diseases
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2031700A (en) Stereotactic apparatus and methods
AU1585999A (en) Methods for the detection and treatment of disease using a glycosyltransferase
AU3552399A (en) Recombinant poliovirus for the treatment of cancer
AU1575697A (en) Compositions and methods for the treatment and diagnosis of cancer
AU3596199A (en) Treatment of celiac disease
AU5042000A (en) Methods of treating proliferative disorders
AU6330999A (en) Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
AU1697197A (en) Immunoconjugate for the treatment of aids
AU5298699A (en) Dnazymes and methods for treating hpv-related disorders
AU8068198A (en) Methods for treating human cancers
IL143212A0 (en) Compositions and methods for the treatment of tumor
IL141426A0 (en) Compositions and methods for the treatment of tumor
AU1710001A (en) Method and arrangement for determining suitable treatment frequency and/or intensity
AU4480997A (en) Screening methods for compounds useful in the treatment of schizophrenia
AU5855899A (en) Method for identifying substances for the treatment of c-jun-mediated disorders
AU2566201A (en) Compounds and methods for the treatment of pain
EP1171051A4 (en) Apparatus and method for the processing of solid materials, including hard tissues

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase